Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a ...

Pfizer may also consider retaining the business, one of the largest over the counter products businesses in the world, operating in 90 countries. It markets two of the ten top-selling consumer ...

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...

Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste.Most ...

Attorney General Todd Rokita has filed a lawsuit alleging that Mylan and Pfizer have conspired to increase EpiPen’s price by ...

Sales of PFE’s COVID Products Declining Sales of Pfizer’s COVID products, Comirnaty and Paxlovid, are declining due to lower demand following the end of the pandemic. However, sales of both ...

Some blame Pfizer. The firm is struggling to replace ... “We knew we could make a consumer product. Our major generational advantage was based on the simplicity of the device,” he says.

Then, this is the segment with the strongest focus in Pfizer's pipeline. If we take a look at the top 10 products in 2023, the ranking is still led by Comirnaty (19% weight), despite the drop in ...

The latest disposal reduced Pfizer's interest in Haleon to 7.3% from 15%. JPMorgan and Morgan Stanley acted as joint global coordinators and joint bookrunners for the sale. GSK sold its remaining 4.2% ...

Pfizer may also consider retaining the business, one of the largest over the counter products businesses in the world, operating in 90 countries. It markets two of the ten top-selling consumer ...